<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01230476</url>
  </required_header>
  <id_info>
    <org_study_id>EMR 62202-832</org_study_id>
    <nct_id>NCT01230476</nct_id>
  </id_info>
  <brief_title>Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally Advanced Nasopharyngeal Carcinoma</brief_title>
  <official_title>Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally Advanced Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Malaya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Serono International SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Malaya</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Standard of care for treatment of nasopharyngeal carcinoma is chemoradiation with concurrent
      cisplatin. Addition of a second agent, cetuximab, which targets nasopharyngeal carcinoma
      cells with high EGFR protein expression, may enhance the effectiveness of radiation and
      result in better tumour control. This study investigates the addition of 2 cycles of
      cisplatin/5FU chemotherapy with cetuximab, followed by cisplatin and cetuximab concurrent
      with radiation, for treatment of locally advanced nasopharyngeal carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>1 year</time_frame>
    <description>Assess the response rate of this combination treatment, as measured by imaging and endoscopy findings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression and overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>To assess the PFS and OS at one year</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cetuximab and chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 cycles of neoadjuvant cisplatin and 5FU (3 weekly), given with weekly cetuximab, followed by 7 doses of weekly cisplatin and cetuximab concurrent with radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Cetuximab loading dose of 400mg/m2, then weekly dose of 250mg/m2 for 12 doses; Neoadjuvant Cisplatin 75mg/m2 D1, 5FU 1000mg/m2 D2-5, for 2 cycles; Concurrent Cisplatin 30mg/m2 given with radiation 70Gy/35fraction/7weeks.</description>
    <arm_group_label>Cetuximab and chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent

          -  Inpatients or outpatients, 18-65 years of age

          -  Histologically confirmed, newly diagnosed locally advanced (UICC/AJCC stage III to
             IVB) nasopharyngeal carcinoma requiring radiotherapy

          -  Evidence of unidimensional measurable disease as per RECIST criteria

          -  No systemic metastatic disease (M0)

          -  ECOG performance status of 0 or 1 at study entry

          -  Effective contraception

          -  White blood cell count ≥ 3,000/mm3 with neutrophils ≥1,500/mm3, platelet count
             ≥100,000/mm3, hemoglobin ≥ 5.6 mmol/L (9 g/dL)

          -  Total bilirubin ≤ 1.5x upper reference range

          -  AST &amp; ALT ≤ 1.5x upper reference range

          -  Glomerular filtration rate &gt; 60 ml/min

          -  Serum creatinine ≤ 1.25x upper reference range

        Exclusion Criteria:

          -  Previous radiotherapy, chemotherapy, surgery (excluding diagnostic biopsy) or any
             investigational drug for the NPC

          -  Concurrent chronic systemic immune therapy, targeted therapy, anti-VEGF therapy or
             EGFR-pathway targeting therapy not indicated in this study protocol

          -  Known hypersensitivity reaction to any of the components of study treatments

          -  Pregnancy or lactation period

          -  Systemic metastatic disease

          -  Clinically relevant coronary artery disease, history of myocardial infarction in the
             last 12 months, or high risk of uncontrolled arrhythmia

          -  Peripheral neuropathy &gt; grade 1

          -  Previous malignancy except basal cell cancer of the skin or preinvasive cancer of the
             cervix

          -  Known alcohol or drug abuse

          -  Medical or psychological conditions that would not permit the patient to complete the
             study or sign informed consent

          -  Legal incapacity or limited legal capacity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gwo Fuang Ho, FRCR</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Malaya</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <state>Wilayah Persekutuan</state>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2010</study_first_submitted>
  <study_first_submitted_qc>October 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2010</study_first_posted>
  <last_update_submitted>May 19, 2017</last_update_submitted>
  <last_update_submitted_qc>May 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Malaya</investigator_affiliation>
    <investigator_full_name>Ho Gwo Fuang</investigator_full_name>
    <investigator_title>Medical Lecturer</investigator_title>
  </responsible_party>
  <keyword>Locally advanced nasopharyngeal carcinoma</keyword>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <keyword>Chemoradiation</keyword>
  <keyword>Cetuximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

